Claims for Patent: 8,486,957

Summary for Patent: 8,486,957

Title:	Chemotherapeutic for inducing an MSH2-dependent apoptotic pathway
Abstract:	A method of treating cancer in a subject in need thereof comprises administering said subject reserpine, yohimbine, an analog thereof, or a pharmaceutically acceptable salt or prodrug thereof, in an amount effective to treat the cancer. Compounds and compositions useful for carrying out the method are also described.
Inventor(s):	Salsbury, Jr.; Freddie R. (Winston-Salem, NC), Scarpinato; Karin D. (Clemmons, NC), King; S. Bruce (Walnut Cove, NC)
Assignee:	Wake Forest University Health Sciences (Winston-Salem, NC)
Application Number:	12/711,306
Patent Claims:	1. A compound of Formula Ia: ##STR00015## wherein: R.sub.1 is methoxy; R.sub.2is: ##STR00016## where each R' is independently selected from H, OH, OCH.sub.3, and COOH, subject to the proviso that at least one R' is COOH; R.sub.3 is hydroxy or loweralkoxy, R.sub.4 is --C(O)OR' or --NHC(O)OR', where R' is H or loweralkyl; or a pharmaceutically acceptable salt or ester thereof. 2. A composition comprising a compound of claim 1 in a pharmaceutically acceptable carrier. 3. The composition of claim 2, further comprising at least one additional chemotherapeutic agent. 4. The composition of claim 3, wherein said additional chemotherapeutic agent is selected from the group consisting of androgens, asparaginase, azathioprine, 5-azacitidine, BCG, bleomycin, busulfan, carbetimer, carboplatin chlorambucil, cisplatin, oxaliplatin, corticosteroids, cyclophosphamide, cytarabine, dacarbazine, dactinomicin, daunomycin, doxorubicin, epirubicin, estrogens, etoposide, fadrazole, 5-flurouracil, gemcitabine, hydroxyurea, ifosfamide, interferon alpha, interferon beta, interferon gamma, an interleukin, isotretinoin, lomustine, melphalan, 6-mercaptopurine, methotrexate, mitomycin-c, mitotane, mitoxantrone, paclitaxel, pentostatin, procabazine, progestins, rituximab, streptozocin, tamoxifen, taxotere, teniposide, thioguanine, thiotepa, topotecan, toremifene, tretinoin, uracil mustard, vinblastine, vincristine and vinorelbine. 5. The compound of claim 1 selected from the group consisting of: ##STR00017## and pharmaceutically acceptable salts thereof.

Details for Patent 8,486,957

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	January 10, 1978		2030-02-24
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997		2030-02-24
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	February 19, 2002		2030-02-24
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	June 22, 2017		2030-02-24